Related Experiment Videos
Pathologic changes in a long-term heterotopic heart transplant survivor
A Pucci1, G Passarino, S Marra
1Dipartimento di Scienze Biomediche e Oncologia Umana, Università degli Studi, Torino.
Cardiologia (Rome, Italy)
|June 1, 1995
Summary
A 10-year-old heterotopic heart transplant recipient showed diffuse atherosclerosis in the allograft. Cyclosporine treatment was associated with increased cell proliferation in the transplanted heart
Area of Science:
- Cardiovascular Pathology
- Transplant Medicine
- Immunosuppression Research
Background:
- Heterotopic heart transplantation is a surgical procedure where a donor heart is placed alongside the recipient's native heart.
- Cyclosporine is a calcineurin inhibitor commonly used as an immunosuppressant to prevent organ rejection.
- Atherosclerosis is a disease characterized by the buildup of plaques in arteries, leading to hardening and narrowing.
Observation:
- Autopsy findings in a 10-year-old patient who underwent heterotopic heart transplantation and received cyclosporine treatment.
- Examination of both the transplanted allograft and the recipient's native heart.
- Assessment of atherosclerotic disease severity and cellular proliferation markers.
Findings:
- The transplanted heart (allograft) exhibited diffuse multivessel atherosclerotic disease.
- The recipient's native heart showed focal atherosclerosis in the coronary arteries and aorta.
- Significantly increased expression of proliferating cell nuclear antigen was observed in the allograft vessels compared to the recipient's vessels.
Implications:
- Cyclosporine treatment may contribute to accelerated or distinct patterns of atherosclerosis in heart allografts.
- Understanding the role of immunosuppression in transplant-associated atherosclerosis is crucial for long-term graft survival.
- Further research is needed to elucidate the mechanisms linking cyclosporine, cell proliferation, and vascular disease in transplanted hearts.